Lilly Launches Byetta In China To Target World's Second Largest Diabetes Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Eli Lilly announced Aug. 23 that the company has launched its GLP-1 agonist Byetta (exenatide) in China, and the drug will be in hospitals in first-tier cities by the end of September
You may also be interested in...
Lilly Diabetes R&D Center Arms Firm For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.
New Diabetes R&D Center Arms Eli Lilly For Battle In China
Lilly’s first R&D center in China will focus on developing therapies that target the genetic profile and dietary habits of Asian diabetes patients.
Novo Nordisk Signs MOU With China's Health Ministry To Launch Patient Education Programs
Novo Nordisk's newest move to increase patient education in China will cost RMB 9 million over three years, a small price to pay to reinvigorate growth slowed by insulin price cuts.